Results 131 to 140 of about 15,296 (199)

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients. [PDF]

Hemasphere, 2023
Ocio EM, Bringhen S, Martinez-Lopez J, Martinez-Lopez J, San-Miguel J, Oliva S, Rodriguez-Otero P, Le Roux N, Dong Y, Doroumian S, Macé S, Mateos MV.   +11 more
europepmc   +1 more source

[More than playing: The therapeutic value of play in comprehensive childcare from primary care]. [PDF]

Aten Primaria
González-Díaz A, Gómez-Salgado J, Suleiman-Martos N, Gómez-Urquiza JL.   +3 more
europepmc   +1 more source

Ocio y negocio

, 1978
"Este Artículo pertenece a la sección Arte, Letras, Espectáculos. "
openaire   +3 more sources

¿Ocio o negocio?

, 1998
ESP
openaire   +1 more source

[Disability and participation in active leisure activities: results from a Chilean population-based survey]. [PDF]

Cad Saude Publica
Chávez-Cunti N, Alarco JJ.
europepmc   +1 more source

[Breastfeeding app updates and recommendations]. [PDF]

An Pediatr (Barc), 2023
Díaz Cano AI, Esplugues A.
europepmc   +1 more source

[Determinants of access to dental health in Spain]. [PDF]

Aten Primaria
Ruiz-Campo S, Zuniga-Jara S, Soria-Barreto K.   +2 more
europepmc   +1 more source

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. [PDF]

Leukemia, 2023
Ocio EM, Perrot A, Bories P, San-Miguel JF, Blau IW, Karlin L, Martinez-Lopez J, Martinez-Lopez J, Wang SY, Bringhen S, Marcatti M, Mateos MV, Rodriguez-Otero P, Oliva S, Nogai A, Le Roux N, Dong L, Macé S, Gassiot M, Fitzmaurice T, Oprea C, Moreau P.   +21 more
europepmc   +1 more source

[Same year, different source: variability in prevalence estimates of exposure to secondhand smoke in Spain]. [PDF]

Aten Primaria
Rey-Brandariz J, Blanco-Ferreiro A, Santiago-Pérez MI, Schiaffino A, Guerra-Tort C, Pérez-Ríos M.   +5 more
europepmc   +1 more source

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial. [PDF]

Haematologica
Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV.   +37 more
europepmc   +1 more source